Aleksandra Schellenberg is a Head of Sustainable Finance Legal at UBS and is based in Zurich. At UBS, Aleksandra, together with 10 brilliant lawyers she leads, provides legal advice on ESG risks across the bank’s operations such as Group sustainability strategy, ESG commitments, sustainable investing, sustainable lending, supply chain, greenwashing, ESG litigation to name a few.
In addition, Aleksandra promotes sustainability outside her business hours. She is a founder and a CEO of Speaktacular.Me (www.speaktacular.me), a free social media platform created for women to be 100% themselves, and where they can anonymously speak to each other on any topic without judgement, and to empower one another.
Peter is The Chief Commercial Officer for Protium Green Solutions Ltd, the London based Green hydrogen solutions provider.
After spending a decade as a hedge fund manager in the early 2000s, Peter moved into renewable energy project development and investment management, and across the next 15 years focused on concluding the development & commissioning of more than 1,000 MW portfolio of wind & solar and battery system investments. Initially working for Deloitte, and then for a project developer owned by the Californian Teachers Pension Fund. Since early 2023 Peter has lead the Protium team in terms of commercializing the hydrogen production facility development process, and is speaking today to share the lessons learned from a specific customer that in his mind are important for the brewing sector to incorporate into their energy transition and decarbonization journey.
Peter is Professionally qualified in the private equity environment and holds a Charter to the Association of Alternative Investment Analyst, is a Financial Modelling and Valuations Analyst and is a Fellow of the SA Institute for Financial Markets. Peter has degrees in science, post graduate in Organizational decision-making and holds an MBA from Henley Business School.
As commercial Director at Avantium, Bart is responsible for the commercialisation and industrialisation efforts of our pioneering bio-plastic PEF. Bart is an experienced executive with a demonstrated history of strategic business development and realised revenue growth in structural thermoplastics and management consulting industry. Driving Innovation, Commercial Excellence and Application Development in specification driven markets. Bart holds an MBA focused on Management of Innovation at TSM Business School, The Netherlands.
Britta Wyss Bisang is the VP of Sustainability and Strategic MarCom of Schoeller Allibert, the leading supplier of returnable and reusable transport packaging in Europe.
Britta has a 20+ years track record in strategy development, ESG/sustainability programs, communications and change management. She is an expert in corporate sustainability and advocacy for a circular economy and has positioned Schoeller Allibert as a sustainability leader in its industry.
Britta holds an MSc in Environmental Sciences from ETH Zurich and has graduated with an Executive MBA from IMD Business School, Lausann
Mark is Partner at MHA Baker Tilly International (BTI) (Ranked 9th largest in the world) specialising in Global Assurance, Financial Turnaround, Fashion & Cosmetics, Food Manufacture & Rural Industries. He leads the MHA UK ESG Audit & Advisory function. He is also engaged in food retail, and consumer industries and a multi award winning turnaround specialist
Mark trained at Macintyre Hudson and has remained with the firm, aside from a 15 year in industry role, building a national educational commercial organisation investing over £100m, Employing 1300 staff, working with 1000s of national and international businesses, leverage GDP in the south east and enable nearly 78,000 students to be educated. He pioneered the world class sustainability Eco Project at Betteshanger park (Kent) (being the longest building in Europe at that time) in a £30m Regeneration project. Mark has been in the C-Suite understanding the challenges facing national and international businesses.
Mark has delivered numerous turnarounds from financial services through to rural businesses, and national institutions.
Mark Charis Rural Policy Group – a think tank and advocate for sustainable rural policy across the United Kingdom linking food & farming to public health and environmental sustainability. The policy group launched its National Green Futures Report in 2021 to set the foundations for a rural-first approach to economic policy-making for a more sustainable UK plc. He is directly connected into Westminster and works on a non partisan basis with government to support the industries MHA Serves.
Mark has won numerous awards for his work including National Finance Director of the year 2007, Accounting for sustainability National award 2012 (ICEAW), National Business Finance Director 2014 (Finance Director) and the Institute of Directors (IOD) blue ribbon award for Governance and Finance excellence in 2018.
He is a Liveryman in the Worshipful Company of Fruiterers, a Member of the Guild of Freemen, A member of the livery of Chartered Accountants, IoD South East Lead for ESG and a member of the CBI’s South East Council.
Dylan Stoy, PSI’s Therapeutic Strategy Director, is dedicated to conducting and executing better clinical studies in PSI’s core therapeutic areas. Dylan has a wealth of experience in the oncology indication, with research interests in targeted drug delivery systems and optimizing the design and conduct of studies. Dylan has overseen clinical research from various roles including onsite research, design and trial conduct, clinical operations oversight, project management, and therapeutic strategy.
Dylan and his team are devoted to making participation for sites and patients in complex oncology studies more attainable and ensuring that both PSI’s teams and your study sites are highly trained and properly supported to handle any challenges your program might encounter. Dylan works closely with the core business units within PSI, overseeing research throughout the study lifecycle, providing strategic leadership to our teams and collaborators (both internally and externally), and delivering corporate-wide trainings to make PSI your full-service CRO for all things oncology.
Steve’s career in life science and healthcare spans more than 40 years. He has led the development and deployment of cloud-based solutions with a focus on driving more integrated approaches to patient-centric trial management. Today, he continues to leverage this deep experience to drive uMotif’s hypergrowth.
Steve was most recently Senior Vice President and General Manager of Oracle Health Sciences. Before that, Steve was at the forefront of advancing the adoption of electronic data capture and was the visionary behind the integrated clinical technology suite introduced by Phase Forward which was acquired by Oracle in 2010.
Steve has been named twice to the prestigious PharmaVoice 100 list. He recently served on the Board of Anju Software and currently sits on Prix Galien’s Digital Media and USA Digital Health Advisory boards. He also served a six-year term on CDISC’s Board.
As Director, Services Solutions at Suvoda, Amanda brings more than 10 years of experience working in client services. Prior to joining Suvoda, she held positions in science and consulting, operations, product development, and technical implementation with various technology vendors and CROs. With her extensive experience in decentralized trials, Amanda also serves as an eConsent expert at Suvoda. Amanda holds a master’s in Organizational Learning and Development from Suffolk University and a master’s in Health Sciences: Clinical Research Administration from George Washington University.
As the chief business officer, Peter is responsible for establishing and executing Frontier’s business development strategy which includes identifying target customers and managing the execution of the company’s sales strategy. Peter is also responsible for identifying opportunities for business growth and creating business partnerships, along with overseeing the activities and performance of the business development team.
Prior to joining Frontier, Peter started the Contract Manufacturing business for Pharmascience in Montreal. He built their US division for over 6 years and is credited for growing that new business vertical to over $200M. Pharmascience is a full service CMO specializing in development and manufacturing of complex oncology injectables.
Peter has over 15 years of experience in the Pharmaceutical industry. His experience spans from preclinical development, to API sales, to Generic injectable manufacturing. He began his career in preclinical safety pharmacology where he lead the business development unit for Huntington Life Sciences in Princeton NJ. Gradually, he worked his way into the Clinical Trial sector and took up a Director of Business Development role for AIT Biosciences in Indianapolis. He later spent 5 years in the API industry and began MSN Pharma’s first US office in Edison NJ.
He received his undergraduate degree from The University of California Irvine in Biology and a Masters Degree in Biotechnology from The University of Pennsylvania (UPENN).
